A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care

Eosinophilic Esophagitis Treatment Observation with DUPIXENT®

Recruiting
1 year or above
All
Phase N/A
350 participants needed
29 Locations

Study Overview

This observational research study is to better understand patients with eosinophilic esophagitis (EoE) who have recently been prescribed DUPIXENT® (dupilumab).

The purpose of this research study is to look at how DUPIXENT is used in normal care of patients with EoE.

Possible benefits to others include a better understanding of EoE and helping to inform research and clinical trial design leading to treatment decisions in this patient population going forward.

Patient questionnaires will measure the following:

  • How EoE makes one feel
  • EoE signs and/or symptoms, eg, how difficult it is to swallow
  • How EoE affects quality-of-life
  • How EoE impacts aspects of daily life
  • How EoE symptoms have changed throughout the study

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Eosinophilic Esophagitis (EoE)
  • Age: 1 year or above
  • Gender: All

Key Inclusion Criteria:

  1. Initiating treatment with DUPIXENT® for EoE according to the USPI
  2. Participants aged ≥12 years and caregivers or legal guardians of participants aged <12 years must be able to understand and complete registry-related questionnaires

Key Exclusion Criteria:

  1. Patients who have a contraindication to DUPIXENT® according to the USPI
  2. Treatment with DUPIXENT® within the 6 months prior to the screening assessment
  3. Participation in an ongoing interventional study on or within 6 months of the baseline assessment. Once enrolled in registry, participation is allowed in other ongoing studies (at the discretion of the registry investigator)

NOTE: Other protocol defined inclusion/exclusion criteria apply

This study investigates eosinophilic esophagitis. It focuses on patients who have recently been prescribed an investigational medication as part of their standard care.

The study evaluates the use of this investigational medication in routine treatment settings. It looks at various aspects like patient experiences, symptoms, and quality of life changes.

  • Who can participate: Participants must be 12 years or older, or caregivers of those under 12 who can complete questionnaires. They must be starting treatment with DUPIXENT® for eosinophilic esophagitis.
  • Study details: Participants will complete questionnaires about how eosinophilic esophagitis affects them, including symptoms and daily life impacts.
Updated on 17 Jun 2026. Study ID: NCT06693531

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
United States Only: Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language